The results of the winning bid of the three provincial alliances, which reduced the price by 90.35%, were announced

basically no small business winning bid1, a maximum price reduction of 90.35 percent, a number of well-known arms enterprises won the bidSeptember 5, Chongqing Municipal Health Insurance Bureau issued "on the public announcement of the three provinces and cities crown expansion balloon joint belt procurement of the results of the proposed enterprise."According to Saibai Blue equipment combing, this pre-expansion group crown expansion balloons are proposed to select enterprises including Hunan Epte, Shanghai Minimally Invasive, Shandong Jiwei, Poco, Lepu, Medtron.Post-expansion group crown expansion balloons are proposed to select enterprises including Hunan Epte, Sano Medical, Shanghai Minimally Invas, Poco, Lepu, Abbott.According to people's network news, this activity has been domestic and foreign production enterprises positive response. On-site, the heart crown balloon procurement is divided into pre-expanded and post-expansion two groups, and the use of expert voting and bidding.Among them, the pre-expansion group produced a total of 6 enterprises to be selected, 6 products to be selected, an average decline of 85.49%, the highest decline of 89.84%;The overall decline of 85.32 percent is expected to save 190 million yuan in health insurance funds for the three provinces and cities.For the specific data of this price reduction, on September 3, Guizhou Province pharmaceutical centralized procurement platform issued "on the publication of the crown balloon centralized procurement enterprise audit results and enterprise representative products notice", announced the lowest price of enterprises hanging online.For example, in the pre-expansion group, the minimum price of the fast-switching balloon expansion catheter (commodity name: Sprinter Legend) proposed by Medtron is 3346.4 yuan;Referring to the average decline of 85.49% and the highest decline of 89.84%, the overall winning bid price may be between 200 yuan and 500 yuan.As in the later expansion group, Abbott's proposed coronary artery balloon dilation catheter (commodity name: NC TREK RX) has a minimum price of 3200 yuan;the minimum price of the non-conforming PTCA balloon expansion catheter to be selected by Lepu Medical is 3010 yuan; the lowest price of the PTCA expansion catheter to be selected byPoco is 2905 yuan; and the minimum price of the post-expansion PTCA balloon catheter to be selected byHunan Epte is 2435.81 yuan.Referring to the average decline of 85.51% and the highest decline of 90.35%, the overall winning bid price may be between 250 yuan and 500 yuan.

2, are the winning bid of large   In addition to the larger decline, another feature of this proposed selection is that large-scale well-known domestic and foreign enterprises won the bid, rather than small enterprises winning the bid.   Comparing the winning results of the crown pulse balloon in Hubei Province, on August 26, Hubei Province Pharmaceutical Price and Tender Procurement Management Service Network released the results of the proposed winning bid for the volume of procurement, of which the proposed crown pulse expansion balloon decreased by 96%.   The proposed enterprises include Shenzhen Shunmei Medical Co., Ltd., Shenzhen Yisinda Medical New Technology Co., Ltd., Ined Medical Technology (Shanghai) Co., Ltd., etc., the above three enterprises quoted 129.9 yuan, 194.5 yuan, 215 yuan, respectively.

the results of the three provincial alliances in Hubei Province are completely different, perhaps because of specific shortlisting or bidding rules.   On August 4, Hubei Province issued the "Hubei Province medical institutions crown expansion balloon belt volume procurement document", the finalist rules require that according to the crown pulse expansion balloon functional properties are divided into two competitive groups, that is, semi-compliance and non-compliance.   The declared enterprises in each group will determine the selected enterprises and prices by means of bidding or negotiating. With the bidding group products, the actual declared enterprises that meet the declaration qualification shall be shortlisted according to their effective quotations from low to high.   On August 20, Guizhou Province issued the three provincial alliance crown expansion balloon joint belt procurement documents, bid rules require that each group of enterprises approved by the qualification certification materials in 4 or more, by the three provinces and cities selected clinical experts and procurement experts in the qualified production enterprises through the enterprise product quality, scale, product distribution capacity, product stability and other factors, after a silent vote, each group of votes from the end of the high ranking, selected finalists.   Then take the bidding method, according to the shortlisted enterprise declared price from low to high, in turn to determine the order of enterprises.   There have been a number of industry insiders on the Cypress Blue device analysis, if the auction more attention to price factors, mainly than the price reduction range or the lowest price, then some small enterprises or "barefoot enterprises" to increase the chances of winning the bid, there may be product quality, clinical use habits and supply issues to be considered.   If the adoption of similar to the 10 provincial alliance or the three provincial alliance of the improved version of the double envelope system, through quality, scale and other factors to determine the finalists, then the possibility of small enterprises winning the bid will be reduced, the possibility of winning the bid of large manufacturers increased, correspondingly, the overall price decline may not be so large.

3, basically complete the domestic   It is understood that coronary dilated balloons are mainly used for the expansion of coronary artery stenosis in cases such as coronary heart disease, with the continuous improvement and development of coronary interventional therapy-related technologies and equipment, cystic catheters play a vital role in interventional therapy.   Since the coronary stent is implanted into the vascular narrow area through the traditional coronary dilation balloon catheter, it can be said that the crown stent of the head is also the main coronary expansion balloon provider in the market.   According to the forward-looking industry research institute data, as early as 2005, China's crown support market in the import of brand products dominated, Medtron, Boston Science, Johnson and Johnson and other brands of the total market share of more than 60%.   But so far, the crown bracket field has basically completed domestic replacement, including major foreign-funded enterprises including Medtron, Boston Science, Johnson and Johnson, etc., in the domestic market share of less than 30%, the main domestic enterprises including minimally invasive, Lepu, Jiwei and so on, the total market share of domestic manufacturers has exceeded 70%.   According to China Industry Information Network data, in the context of the aging of coronary heart disease, aging of the population, and the continuous promotion of graded diagnosis and treatment, it is expected that in the next 3-5 years, the operation of persetretic coronary artery interventional therapy (PCI) will continue to maintain an annual growth rate of about 13%-16%. It is estimated that by 2022, the number of coronary heart disease intervention cases in China will exceed 1 million, and the total number of stent implants should exceed 2 million. As a result, the use of coronary expansion balloons will also increase year by year.   In addition, according to the Analysis of China Industrial Information Network, with the increase in the number of stent use, the problem of intrast bracket stenosis (ISR) is becoming more and more serious, and in the current ISR treatment program, coronary artery bypass transplantation risk factors and taboos are more, re-placed stent may trigger the risk of re-ISR and other multiple stents placed.   In this case, drug-coated balloons have become a new interventional treatment technology, which has been widely used in Europe and the United States.
(
Cyrus Blue Equipment
)